NCT01693081View on ClinicalTrials.gov

Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2009

Conditions
Parkinson's Disease
Interventions
DRUG

VR040/Aspirair® inhaler

Dry Powder inhaled apomorphine

DRUG

placebo

Trial Locations (9)

11000

Institute of Neurology Clinical Center Serbia Dr Subotica 6, Belgrade

11 000

Neurology Clinical Military Medical Academy, Crnotravska 17, Belgrade

CF14 4XW

University Hospital, Wales, Cardiff

G51 4TF

Department of Neurology, Southern General Hospital, Glasgow

L9 7LJ

The Walton Centre, Liverpool

LL30 1LB

Llandudno Hospital, Llandudno

NG24 4DE

Newark Hospital, Newark

OX2 6HE

Neurology Dept, Radcliffe Infirmary, Oxford

RM7 0BE

Essex Neurosciences, UnitOld Church Hospital, Essex, Romford Essex

All Listed Sponsors
collaborator

Vectura Limited

INDUSTRY

lead

South Glasgow University Hospitals NHS Trust

OTHER

NCT01693081 - Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease | Biotech Hunter | Biotech Hunter